Zura Bio Limited (ZURA)
| Market Cap | 454.48M +361.6% |
| Revenue (ttm) | n/a |
| Net Income | -106.13M |
| EPS | -1.07 |
| Shares Out | 94.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,053,757 |
| Open | 4.420 |
| Previous Close | 4.540 |
| Day's Range | 4.350 - 4.840 |
| 52-Week Range | 0.980 - 7.440 |
| Beta | 0.09 |
| Analysts | Buy |
| Price Target | 13.00 (+171.4%) |
| Earnings Date | May 7, 2026 |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and C... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ZURA stock is "Buy." The 12-month stock price target is $13.0, which is an increase of 171.40% from the latest price.
News
Zura Bio reports Q1 EPS (22c) vs (19c) last year
“We entered the second quarter with a strengthened balance sheet and strengthened team, reflecting growing conviction in bispecific approaches and increased appreciation for IL-17 and BAFF biology” sa...
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of pa...
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improv...
Zura Bio management to meet virtually with Clear Street
Virtual Meeting to be held on April 23 hosted by Clear Street.
Zura Bio management to meet with Piper Sandler
Meeting to be held in Boston on March 30-31 hosted by Piper Sandler.
Zura Bio price target lowered to $15 from $16 at Oppenheimer
Oppenheimer lowered the firm’s price target on Zura Bio (ZURA) to $15 from $16 and keeps an Outperform rating on the shares after the company reported year-end financial results and
Zura Bio reports FY25 EPS ($1.06) vs (60c) last year
“2025 was a year of strong execution for Zura, marked by meaningful progress across our Phase 2 programs and a disciplined focus on advancing our clinical strategy,” said Sandeep Kulkarni,
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully imp...
Zura Bio Transcript: Leerink Global Healthcare Conference 2026
The company is prioritizing tibulizumab, a first-in-class bispecific antibody targeting IL-17 and BAFF, with pivotal phase II data in hidradenitis suppurativa expected in Q4 and systemic sclerosis data in the first half of 2027. Strategic focus is on robust trial design, market differentiation, and readiness for phase III advancement.
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully imp...
Zura Bio to Participate in Upcoming Investor Conferences
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to...
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully imp...
Zura Bio 18.2M share Spot Secondary priced at $6.25
The deal range was $6.00-$6.25. Leerink, Piper Sandler and Cantor Fitzgerald acted as joint book running managers for the offering.
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the ...
Zura Bio announces common stock offering, amount not stated
Leerink Partners, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering.
Zura Bio spot secondary offering; price range $6.00-$6.25
Leerink Partners, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering.
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients wi...
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to...
Zura Bio management to meet with Piper Sandler
Meeting to be held on February 19 hosted by Piper Sandler.
Zura Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Leadership transition brings renewed focus on tibulizumab, a bispecific antibody targeting IL-17A and BAFF, with pivotal phase II readouts in hidradenitis suppurativa and systemic sclerosis expected in the next 12-18 months. Robust study design and pipeline expansion are prioritized.
Wedbush bullish on Zura Bio, initiates with an Outperform
As previously reported, Wedbush initiated coverage of Zura Bio (ZURA) with an Outperform rating and $15 price target The firm sees a favorable near- and long-term setup with shares likely
Zura Bio initiated with an Outperform at Wedbush
Wedbush initiated coverage of Zura Bio (ZURA) with an Outperform rating and $15 price target
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to...
Zura Bio CEO Robert Lisicki resigns, Sandeep Kulkarni succeeds
Zura Bio (ZURA) announced the appointment of Sandeep Kulkarni as CEO, effective January 21. Kulkarni will also continue serving as a director of Zura. Kulkarni succeeds Kim Davis, who has
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to...